H.C. Wainwright lifts target for Kodiak Sciences stock to USD 126

Published on 10/27/2026 at 20:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter earnings per share missed estimates by USD 0.09 on August 13, 2026. Kodiak Sciences stock costs EUR 81.10 on October 27, 2026 after hours.

Analyst target and earnings

H.C. Wainwright raised its Kodiak target from USD 96.00 to USD 126.00 on October 12, 2026.
Second-quarter adjusted earnings per share were USD -1.05 against a USD -0.96 consensus estimate.
Kodiak Sciences stock costs EUR 81.10 at Lang & Schwarz on October 27, 2026 at 8:23 p.m. CEST.

KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences (US50015M1099) is trading at EUR 81.10 at Lang & Schwarz on October 27, 2026 at 8:23 p.m. CEST. MarketBeat reported on October 12, 2026 that H.C. Wainwright raised its target from USD 96.00 to USD 126.00 and maintained a Buy rating.

Target reaches 38.63 percent above Nasdaq price

The USD 126.00 target stood 38.63 percent above the USD 90.86 Nasdaq price on October 27, 2026. H.C. Wainwright's target therefore provided a materially different reference point from the latest US quotation, although the target is an analyst view rather than company guidance.

Stock remains below its yearly high

Kodiak Sciences had a market capitalization of USD 5.7 billion and a 52-week range of USD 15.83 to USD 104.00 as of October 27, 2026. The latest Nasdaq price of USD 90.86 was 12.63 percent below that high, while the stock remained 473.91 percent above its 52-week low.

Quarterly loss keeps the focus on development

MarketBeat said Kodiak reported second-quarter earnings per share of USD -1.05 on August 13, 2026, compared with a consensus estimate of USD -0.96. The USD 0.09 shortfall keeps operating progress and financing capacity central to the biotechnology company's investment case.

Kodiak Sciences described three late-stage clinical programs in its September 2026 investor-relations materials. The company also said it planned a multi-indication biologics license application for Zenkuda in 2026, covering wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Price and company milestones

The EUR 81.10 quotation at Lang & Schwarz on October 27, 2026 at 8:23 p.m. CEST places the German investor view below the USD 104.00 52-week high observed for the Nasdaq listing. Kodiak's next valuation test is whether clinical progress can narrow the distance between its current loss profile and the USD 126.00 analyst target. The price was trading at EUR 81.10 at Lang & Schwarz on October 27, 2026 at 8:23 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.